Qiagen acquires Genaco in $40M deal
Qiagen has acquired Huntsville, AL-based Genaco Biomedical Products for $22 million in cash plus shares. The deal also includes up to $18 million in milestone payments. The deal gives Qiagen ownership of Genaco's expertise in multiplexing technology for diagnostics work. In multiplexing, a diagnostic test screens for more than 10 targets when patients present symptoms that could be attributed to a variety of causes. Multiplexing, for example, could be used to test for hospital acquired infections.
"We believe that multiplexed molecular diagnostic testing is increasingly attractive due to current trends in molecular diagnostics and research, where identifying pathogens and disease markers against a broad panel of potential markers in a quick and in a cost efficient manner is developing into a significant need," said Peer M. Schatz, Qiagen's CEO.
- here's the release on the deal
Related Article:
Qiagen enters deal to buy Gentra Systems. Report
Comments
Post new comment
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets

